Table 1.
Baseline characteristics of SARS-CoV-2 positive participants by treatment group.
| Primary Analysis Populationa |
Concurrently and Eligible randomised population |
|||
|---|---|---|---|---|
| Ivermectin (N = 2250) | Usual Care (N = 3388) | Ivermectin (N = 2250) | Usual Care (N = 1869) | |
| Age, years | ||||
| mean(SD) | 51·2 (13·0) | 55·6 (12·9) | 51·2 (13·0) | 51·8 (12·7) |
| 18–49 | 932 (41%) | 912 (27%) | 932 (41%) | 734 (39%) |
| 50–64 | 959 (43%) | 1460 (43%) | 959 (43%) | 828 (44%) |
| 65 and over | 359 (16%) | 1016 (30%) | 359 (16%) | 307 (16%) |
| Sex, n(%) | ||||
| Female | 1315 (58%) | 1972 (58%) | 1315 (58%) | 1149 (61%) |
| Male | 933 (41%) | 1412 (42%) | 933 (41%) | 719 (38%) |
| Other | 0 | 3 (<1%) | 0 | 1 (<1%) |
| Missing, n(%) | 2 (<1%) | 1 (<1%) | 2 (<1%) | 0 |
| Ethnicity, n(%)b | ||||
| White | 2140 (95%) | 3191 (94%) | 2140 (95%) | 1792 (96%) |
| Mixed background | 35 (2%) | 35 (1%) | 35 (2%) | 26 (1%) |
| South Asian | 30 (1%) | 110 (3%) | 30 (1%) | 26 (1%) |
| Black | 11 (<1%) | 13 (<1%) | 11 (0%) | 7 (0%) |
| Other | 34 (2%) | 38 (1%) | 34 (2%) | 18 (1%) |
| Missing, n(%) | 0 | 1 (<1%) | 0 | 0 |
| IMD quintile, n(%) | ||||
| 1 (Most deprived) | 253 (11%) | 460 (14%) | 253 (11%) | 221 (12%) |
| 2 | 324 (14%) | 528 (16%) | 324 (14%) | 280 (15%) |
| 3 | 460 (20%) | 646 (19%) | 460 (20%) | 355 (19%) |
| 4 | 531 (24%) | 779 (23%) | 531 (24%) | 429 (23%) |
| 5 (Least deprived) | 682 (30%) | 975 (29%) | 682 (30%) | 584 (31%) |
| Duration of illness prior to randomisation, median(IQR) | 4·0 (3·0 to 7·0) | 5·0 (3·0 to 8·0) | 4·0 (3·0 to 7·0) | 4·0 (3·0 to 7·0) |
| Smoking status, n(%) | ||||
| Current smoker | 147 (7%) | 223 (7%) | 147 (7%) | 127 (7%) |
| Former smoker | 755 (34%) | 1199 (35%) | 755 (34%) | 609 (33%) |
| Never smoker | 1333 (59%) | 1931 (57%) | 1333 (59%) | 1114 (60%) |
| Missing, n(%) | 15 (1%) | 35 (1%) | 15 (1%) | 19 (1%) |
| Received SARS-CoV-2 vaccination, n(%) | 2110 (94%) | 2227 (66%) | 2110 (94%) | 1764 (94%) |
| Comorbidity, n(%) | 1524 (68%) | 2467 (73%) | 1524 (68%) | 1269 (68%) |
| Have you taken antibiotics since your illness started, n(%)d | 83 (4%) | 186 (5%) | 83 (4%) | 81 (4%) |
| Missing, n(%) | 0 | 2 (<1%) | 0 | 0 |
| Use of healthcare services at baseline | ||||
| GP, n(%) | 338 (15%) | 630 (19%) | 338 (15%) | 266 (14%) |
| Other primary care services, n(%) | 72 (3%) | 163 (5%) | 72 (3%) | 58 (3%) |
| NHS 111, n(%) | 139 (6%) | 258 (8%) | 139 (6%) | 111 (6%) |
| A&E, n(%) | 29 (1%) | 45 (1%) | 29 (1%) | 21 (1%) |
| Other healthcare services, n(%) | 63 (3%) | 79 (2%) | 63 (3%) | 47 (3%) |
| Baseline wellbeing score, mean(SD) | 4·9 (1·4) | 4·9 (1·4) | 4·9 (1·4) | 4·9 (1·4) |
| Missing, n(%) | 0 | 1075 (32%) | 0 | 0 |
| Day 1 wellbeing score, mean(SD) | 5·1 (1·4) | 5·2 (1·5) | 5·1 (1·4) | 5·2 (1·4) |
| Missing, n(%) | 143 (6%) | 370 (11%) | 143 (6%) | 119 (6%) |
| Well-being (WHO5 Questionnaire)e, mean(SD) | 57·1 (23·3) | 52·8 (24·8) | 57·1 (23·3) | 56·3 (23·7) |
| Missing, n(%) | 0 | 2 (<1%) | 0 | 0 |
3 E.g. angina, heart attack, heart failure, atrial fibrillation, valve problems.
a
Includes participants randomised before the ivermectin arm was open.
b
Data on ethnicity were collected retrospectively via notes review before July 2020.
d
Includes Ramipril, Lisinopril, Perindopril, Captopril or Enalapril.
e
Includes five items relating to wellbeing measured on a five-point scale; a total score is computed by summing the scores to the five individual questions to give a raw score of 0–25, which is then multiplied by 4 to give the final score from 0, representing the worst imaginable wellbeing, to 100, representing the best imaginable wellbeing.